Skip to main content
. 2017 Mar 7;8(17):29013–29027. doi: 10.18632/oncotarget.15994

Figure 4. α2,3-sialylation inhibitor SsaI affects EGFR signaling and synergizes with TKI.

Figure 4

(A) Quantification of EGFR and phospho-EGFR in ES2 cells treated with 100μM SSaI or DMSO control for 72h; GAPDH was used as control (same GAPDH as in Figure 3). (B) Intraperitoneal tumors from B6 mice treated with either SsaI or DMSO control were stained by the Duolink in situ IHC staining kit to analyze for ST3GalI and EGFR. (C) ES2 cells were treated with 100μM SsaI and 5μm AG1478 (EGFR inhibitor) were subjected to Transwell matrigel invasion assay. Total numbers of cells were counted in 7 to 10 random fields. Data shown are the mean ± SD of 3 separate experiments. (D) Synergy between ST3GalI and EGFR were determined by treating ES2 cells with either SsaI orAG1478 (EGFR inhibitor) or both for 48h followed by determination of their effects on cell proliferation rate. Data shown are the mean ± SD of 3 independent experiments. (E) A proposed mechanism of the interaction between ST3GalI and the EGFR signaling pathway.